Whole transcriptome analysis; human atrial natriuretic peptide during perioperative period for completely resected non-small cell lung cancer: a multicentre, open-label, randomised controlled trial

UMIN ID: UMIN000019627

Registered date:04/11/2015

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: non-small cell lung cancer
• Date of first enrollment: 2015/11/04
• Target sample size: 500
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

A: Lung cancer surgery with hANP treatment [Patients in the hANP group receive human ANP (0.025 microgram/kg/min for 3 days), which is started more than two hours before surgery]
B: Surgery alone

Outcome(s)

• Primary Outcome: Clinicopathological character, overall survival, disease-free survival and gene differentiation (including microRNA, cell free DNA, and MUC4 gene mutation)

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1. Thin-section CT fulfills the proportion of maximum diameter of the tumor itself to consolidation is less than 0.25. 2. Patient with active the other concurrent malignant diseases. 3. Women during pregnancy or breast-feeding. 4. Psychosis. 5. Systemic steroids or immunosuppressive agents medication. 6. Uncontrollable infectious disease, autoimmune disease, or the other severe comorbidities. 7. History of right ventricular infarction. 8. Severe hypotension 9. Other conditions judged ineligible by physician

Related Information

• Primary Sponsor: National Cerebral and Cardiovascular Center
• Source(s) of Monetary Support: Shionogi & Co., Ltd.